Table 3 Quality of life of mRCC patients at baseline and 3 months after treatment with sorafenib and sunitinib
SF-36 dimension | At baseline (score) | P value | Three months after treatment (score) | P value | ||
|---|---|---|---|---|---|---|
Sorafenib group (n = 110) | Sunitinib group (n = 74) | Sorafenib group (n = 110) | Sunitinib group (n = 74) | |||
PF | 68.9 ± 20.9 | 67.8 ± 19.5 | 0.548 | 66.7 ± 24.0 | 67.1 ± 20.3 | 0.914 |
RP | 38.2 ± 36.6 | 45.6 ± 34.2 | 0.167 | 36.5 ± 37.5 | 42.7 ± 40.1 | 0.527 |
BP | 77.2 ± 16.0 | 78.7 ± 20.2 | 0.587 | 76.2 ± 16.7 | 77.4 ± 19.7 | 0.646 |
GH | 56.0 ± 16.3 | 54.4 ± 20.2 | 0.531 | 54.7 ± 15.1 | 50.8 ± 19.4 | 0.152 |
VT | 70.1 ± 20.6 | 71.0 ± 16.1 | 0.759 | 68.7 ± 21.7 | 69.3 ± 15.8 | 0.858 |
SF | 80.5 ± 18.6 | 82.1 ± 15.7 | 0.531 | 78.5 ± 19.2 | 80.2 ± 17.3 | 0.571 |
RE | 59.1 ± 6.3 | 63.1 ± 33.4 | 0.452 | 55.5 ± 39.7 | 58.6 ± 37.4 | 0.594 |
MH | 71.1 ± 12.5 | 75.2 ± 9.8 | 0.050 | 69.7 ± 15.7 | 75.8 ± 14.4 | 0.055 |